5. Use of therapies other than oral prednisone and conventional immunosuppressors, that can interfere in the clinical course of the disease (e.g. intravenous [IV] prednisolone bolus, methotrexate, dapsone, sulfasalazine, tetracyclines, nicotinamide, plasmapheresis/ plasma exchange, immunoadsorption and IVIg) within 2 months prior to study entry.